SG11201503946UA - Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease - Google Patents

Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Info

Publication number
SG11201503946UA
SG11201503946UA SG11201503946UA SG11201503946UA SG11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA SG 11201503946U A SG11201503946U A SG 11201503946UA
Authority
SG
Singapore
Prior art keywords
amelioration
prevention
treatment
viral disease
pyrimidone derivatives
Prior art date
Application number
SG11201503946UA
Other languages
English (en)
Inventor
Andrea Wolkerstorfer
Oliver Szolar
Norbert Handler
Helmut Buschmann
Stephen Cusack
Mark Smith
Sung-Sau So
Ronald Charles Hawley
Achyutharao Sidduri
Zhuming Zhang
Original Assignee
Savira Pharmaceuticals Gmbh
Hoffmann La Roche
European Molecular Biology Lab Embl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50070507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201503946U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Savira Pharmaceuticals Gmbh, Hoffmann La Roche, European Molecular Biology Lab Embl filed Critical Savira Pharmaceuticals Gmbh
Publication of SG11201503946UA publication Critical patent/SG11201503946UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201503946UA 2013-01-08 2014-01-07 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease SG11201503946UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750017P 2013-01-08 2013-01-08
PCT/EP2014/050165 WO2014108406A1 (en) 2013-01-08 2014-01-07 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
SG11201503946UA true SG11201503946UA (en) 2015-09-29

Family

ID=50070507

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503946UA SG11201503946UA (en) 2013-01-08 2014-01-07 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Country Status (21)

Country Link
US (1) US9045486B2 (de)
EP (1) EP2943495B1 (de)
JP (1) JP2016518305A (de)
KR (1) KR20150103285A (de)
CN (1) CN104918942A (de)
AR (1) AR094378A1 (de)
AU (1) AU2014204889A1 (de)
BR (1) BR112015012693A2 (de)
CA (1) CA2894642A1 (de)
CL (1) CL2015001916A1 (de)
CR (1) CR20150337A (de)
EA (1) EA201591291A1 (de)
HK (2) HK1211286A1 (de)
IL (1) IL239656A0 (de)
MA (1) MA38323B1 (de)
MX (1) MX2015008293A (de)
PE (1) PE20151722A1 (de)
PH (1) PH12015501517A1 (de)
SG (1) SG11201503946UA (de)
TW (1) TW201443053A (de)
WO (1) WO2014108406A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12015501492B1 (en) 2013-01-08 2015-09-28 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
KR102468319B1 (ko) 2013-09-12 2022-11-16 얀센 바이오파마, 인코퍼레이트. 아자-피리돈 화합물 및 이의 용도
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
MY189144A (en) 2015-04-28 2022-01-28 Shionogi & Co Substituted polycyclic pyridone derivatives and prodrugs thereof
LT3428170T (lt) 2015-04-28 2021-02-10 Shionogi & Co., Ltd Policiklinis piridono darinys nuo gripo ir jo provaistas
US9988390B2 (en) 2015-10-30 2018-06-05 F. Hoffmann-La Roche Ag Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
MA44080A (fr) 2015-12-15 2018-10-24 Shionogi & Co Médicament pour traiter la grippe caractérisé en ce qu'il comprend une combinaison d'un inhibiteur d'endonucléase coiffe-dépendante avec un médicament antigrippal
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017153919A1 (en) 2016-03-08 2017-09-14 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6961963B2 (ja) * 2016-04-01 2021-11-05 三菱ケミカル株式会社 フルフラールの製造方法
JP6957518B2 (ja) * 2016-05-20 2021-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 感染症の治療のための酸素、硫黄および窒素リンカーを有する新規ピラジン化合物
CN109311847B (zh) 2016-05-31 2021-07-06 卡尔维斯塔制药有限公司 作为血浆激肽释放酶抑制剂的吡唑衍生物
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
AR109315A1 (es) 2016-08-10 2018-11-21 Shionogi & Co Composiciones farmacéuticas que contienen derivados de piridona policíclica sustituida y profármaco de las mismas
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
US11234939B2 (en) 2017-11-29 2022-02-01 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
SG11202007718SA (en) 2018-02-28 2020-09-29 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
EP4010333A1 (de) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasmakallikreininhibitoren
JP2023519870A (ja) * 2020-03-25 2023-05-15 エスアールアイ インターナショナル インフルエンザウイルスエンドヌクレアーゼの三環式阻害剤
EP4074317A1 (de) 2021-04-14 2022-10-19 Bayer AG Phosphorderivate als neuartige sos1-inhibitoren
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof
US20240199558A1 (en) 2022-10-19 2024-06-20 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx3cr1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
EP1725554A1 (de) 2004-03-09 2006-11-29 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv-integrasehemmer
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
US20070072831A1 (en) 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
AU2006272521A1 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
EP2412708A4 (de) 2009-03-26 2014-07-23 Shionogi & Co Substituiertes 3-hydroxy-4-pyridonderivat
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
EP2444400B1 (de) 2009-06-15 2018-03-28 Shionogi&Co., Ltd. Substituiertes polyzyklisches carbamoylpyridonderivat
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
RU2608519C2 (ru) * 2010-09-24 2017-01-19 Шионоги энд Ко. Лтд. Пролекарственная форма замещенного полициклического производного карбамоилпиридона

Also Published As

Publication number Publication date
PE20151722A1 (es) 2015-11-19
EP2943495A1 (de) 2015-11-18
CL2015001916A1 (es) 2016-01-22
TW201443053A (zh) 2014-11-16
US9045486B2 (en) 2015-06-02
MA38323B1 (fr) 2018-05-31
JP2016518305A (ja) 2016-06-23
AR094378A1 (es) 2015-07-29
CA2894642A1 (en) 2014-07-17
US20140194431A1 (en) 2014-07-10
MA38323A1 (fr) 2017-02-28
EP2943495B1 (de) 2016-12-28
EA201591291A1 (ru) 2015-12-30
IL239656A0 (en) 2015-08-31
HK1211286A1 (en) 2016-05-20
HK1212686A1 (zh) 2016-06-17
CR20150337A (es) 2015-11-02
AU2014204889A1 (en) 2015-06-11
BR112015012693A2 (pt) 2017-07-11
KR20150103285A (ko) 2015-09-09
CN104918942A (zh) 2015-09-16
WO2014108406A1 (en) 2014-07-17
PH12015501517A1 (en) 2015-11-09
MX2015008293A (es) 2016-06-02

Similar Documents

Publication Publication Date Title
HK1212686A1 (zh) 嘧啶酮衍生物和它們用於治療、改善或預防病毒疾病的用途
HK1211289A1 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
HK1216251A1 (zh) 吡唑並吡咯烷衍生物及其治病作用
HK1205128A1 (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease 7--
HK1212688A1 (zh) 吡啶酮衍生物及其在治療、改善或預防病毒疾病中的用途
IL245698A0 (en) Purines are converted in positions 2 and 6 and their use for the treatment of tumors
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
HK1199881A1 (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease -4-
HK1199640A1 (en) Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
HK1211288A1 (en) Naphthyridinone derivatives and their use in the treatment,amelioration or prevention of a viral disease
HRP20182167T1 (hr) Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba
ZA201600894B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
HUE047636T2 (hu) Arginin csontízületi gyulladás kezelésében és/vagy megelõzésében történõ alkalmazásra